Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Innovent Biologics logo — To develop and commercialize high-quality biopharmaceuticals...

Innovent Biologics

To develop and commercialize high-quality biopharmaceuticals that are affordable to ordinary people

Founded 2011 China Suzhou, China 846 employees Post Ipo Equity Biopharma, Biotechnology +1

General Information

Company Name Innovent Biologics
Founded Year 2011
Location China Suzhou, China +5
Employees 846
Industries Biopharma, Biotechnology, Manufacturing
Funding Stage Post Ipo Equity
Social

Get notified when Innovent Biologics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Innovent Biologics

Innovent Biologics is a biopharmaceutical company established in 2011 with a commitment to develop and commercialize high-quality innovative medicines. The company focuses on treating major diseases such as cancer. It was publicly listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK on 31 October, 2018. Innovent has developed a fully-integrated multi-functional platform including R&D, CMC, clinical development, and commercialization capabilities, resulting in a robust pipeline of 23 valuable assets in various therapeutic areas. Notably, 4 products, including TYVYT®, BYVASDA®, SULINNO®, and HALPRYZA®, have been officially approved for marketing in China, with additional assets in phase III or pivotal clinical trials. The company has invested in a biopharmaceutical production facility operating under global standards with clinical and commercial facilities compliant with cGMP standards of NMPA, FDA, and EMA. Innovent has also established a strong international team of advanced talents and entered into strategic cooperation with leading pharmaceutical companies like Eli Lilly and Incyte. Most recently, Innovent secured a Post-IPO Equity investment on 04 August 2022. As a result, the company continues on its path to realizing its slogan of developing and commercializing high-quality biopharmaceuticals that are affordable to ordinary people.

Taxonomy: Biopharmaceuticals, Monoclonal Antibodies, Biosimilars, Drug Development, Cancer Treatment, Metabolic Diseases, Autoimmune Diseases, Biologics Manufacturing, Clinical Trials, Commercialization, R&D, Global Standard Compliance, Funding, Strategic Partnerships, International Market Expansion

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 04 Aug 2022
Series E •••••• - 27 Apr 2018
Series D •••••• - 29 Nov 2016
Series C •••••• - 22 Jan 2015
Series B •••••• - 16 Nov 2012

View All 6 Funding Rounds

Latest News

View All
Akeso’s lung cancer drug reduces death risk by 34%, marking the first Chinese drug at ASCO’s top sta... — Thenextweb
Akeso’s lung cancer drug reduces death risk by 34%, marking the first Chinese drug at ASCO’s top stage in 61 years
Thenextweb Jun 01, 2026

Innovent Biologics Alternatives & Competitors

Innovent Biologics vs
BioSyngen
BioSyngen Singapore

A clinical stage biotech developing first-in-class cell therapies targeting solid and liquid tumors.

Series Unknown
20 employees
Biotechnology
Compare Innovent Biologics vs BioSyngen
Innovent Biologics vs
Oryzon Genomics SA
Oryzon Genomics SA Spain

Pioneering personalized medicine in epigenetics

IPO
60 employees
Compare Innovent Biologics vs Oryzon Genomics SA
Innovent Biologics vs
Akeso Biopharma
Akeso Biopharma China

First in class and best in class therapeutic antibodies for patients worldwide. #9926.HK

Series D
105 employees
Biopharma, Biotechnology
Compare Innovent Biologics vs Akeso Biopharma

FAQ About Innovent Biologics

To develop and commercialize high-quality biopharmaceuticals that are affordable to ordinary people
Innovent Biologics was founded in 2011.
Innovent Biologics is headquartered in Suzhou, China.
Innovent Biologics operates in the following industries: Biopharma, Biotechnology, Manufacturing.
Innovent Biologics has approximately 846 employees.
Innovent Biologics has completed 6 funding rounds. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Innovent Biologics include BioSyngen, Oryzon Genomics SA, Akeso Biopharma, BIOCAD, Antharis Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Innovent Biologics and BioSyngen are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Innovent Biologics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes